Mohammad Reza Zamani, Martin Hadzima, Kristyna Blazkova, Vladimír Šubr, Tereza Ormsby, Javier Celis-Gutierrez, Bernard Malissen, Libor Kostka, Tomáš Etrych, Pavel Šácha, Jan Konvalinka
Immune checkpoint blockade (ICB) using monoclonal antibodies against programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) is the treatment of choice for cancer immunotherapy. However, low tissue permeability, immunogenicity, immune-related adverse effects, and high cost could be possibly improved using alternative approaches. On the other hand, synthetic low-molecular-weight (LMW) PD-1/PD-L1 blockers have failed to progress beyond in vitro studies, mostly due to low binding affinity or poor pharmacological characteristics resulting from their limited solubility and/or stability...
April 27, 2024: Journal of Biological Chemistry